WHY WE EXIST
For what matters in everyday life.
Our work is guided by what matters beyond a clinical endpoint: the everyday realities, hopes and challenges of people living with neurological diseases and their families.

Mobility
Restoring the ability to move and engage with the world with greater confidence and comfort.

Independence
Preserving the freedom to live life on one's own terms, with less reliance on others for daily tasks.

Connection
Staying connected to the people and communities who matter most, without the limitations imposed by symptoms.

Complex diseases. Complementary mechanisms.
Our approach investigates how complementary therapeutic mechanisms can work together to address the biological complexity of neurological disease. Our goal is to develop treatments that help preserve function and everyday independence. Each combination must be evaluated on its own scientific and clinical evidence.

OUR LEAD PROGRAM
LUT001 for CMT1A
LUT001 (formerly PXT3003) is an investigational low-dose oral combination with a development history spanning Phase 2, Phase 3 studies and long-term follow-up. PLEO-CMT reported a favorable result; PREMIER showed trends of efficacy; a separate China Phase 3 study reported a positive primary endpoint. Lutetia is assessing the complete record to define the next development strategy.
One lead program.
Three research priorities.
LUT001 anchors our development strategy. Our research priorities extend into next-generation CMT1A, ALS and Alzheimer’s disease.
Next-generation CMT1A
Explore combinations and novel components that could build on the LUT001 approach.
LUT002 — ALS
Investigate multimodal strategies addressing complementary disease mechanisms in amyotrophic lateral sclerosis.
LUT003 — Alzheimer’s disease
Explore rational combinations for complex disease biology.
An international ambition. An evidence-led path.
Lutetia is preparing its development strategy for the United States and Europe, with Japan under evaluation. Clinical evidence, manufacturing requirements and regulatory feedback will guide the next decisions.
The China program is led separately by Tasly/GeneNet.



